Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review.

Authors :: Takahashi K
Kato R
Ikarashi D
Matsuura T
Maekawa S
Kanehira M
Takata R
Sugimura J
Abe T
Obara W
Source :: IJU case reports [IJU Case Rep] 2023 Dec 27; Vol. 7 (2), pp. 131-135. Date of Electronic Publication: 2023 Dec 27 (Print Publication: 2024).
Publication Year :: 2023
Abstract: Introduction: Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment.<br />Case Presentation: The first case was of a 72-year-old woman who underwent robot-assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 90-week follow-up. The second case was of a 41-year-old woman referred to our hospital and presented with translocation renal cell carcinoma metastasis to a para-aortic lymph node. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 43-week follow-up.<br />Conclusion: The outcomes of these cases indicate that avelumab-axitinib therapy has a long-term antitumor effect in some patients with tRCC.<br />Competing Interests: The authors declare no conflicts of interest.<br /> (© 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.)

Full Text Access

Tools